Usted buscó: mofetilmikofenolata (Esloveno - Inglés)

ena kapsula vsebuje 250 mg mofetilmikofenolata
each capsule contains 250 mg mycophenolate mofetil.

ena tableta vsebuje 500 mg mofetilmikofenolata.
each tablet contains 500 mg mycophenolate mofetil

vsaka tableta vsebuje 500 mg mofetilmikofenolata.
each tablet contains 500 mg mycophenolate mofetil.

ml pripravljene suspenzije vsebuje 1 g mofetilmikofenolata.
ml suspension contains 1 g mycophenolate mofetil when reconstituted.

ozadje teratogenosti in mutagenosti mofetilmikofenolata pri ljudeh
background information on mycophenolate mofetil teratogenicity and mutagenicity in humans.

5 ml pripravljene suspenzije vsebuje 1 g mofetilmikofenolata.
5 ml of the reconstituted suspension contains 1 g of mycophenolate mofetil.

mofetilmikofenolata ne zasledimo v plazmi po peroralni uporabi.
mycophenolate mofetil is not measurable systemically in plasma following oral administration.

35 g mofetilmikofenolata v 110 g praška za peroralno suspenzijo
35 g of mycophenolate mofetil in 110 g powder for oral suspension

aktivni presnovek mofetilmikofenolata je mikofenolna kislina (mfk).
mycophenolic acid (mpa) is the active metabolite of mycophenolate mofetil.

ustreznih podatkov o uporabi zdravila mofetilmikofenolata pri nosečnicah ni.
there is limited data from the use of mycophenolate mofetil in pregnant women.

ena viala vsebuje ekvivalent 500 mg mofetilmikofenolata v obliki klorovodikove soli.
each vial contains the equivalent of 500 mg mycophenolate mofetil as the hydrochloride salt.

to poglavje bo vsebovalo pomembne informacije o teratogenosti in mutagenosti mofetilmikofenolata.
this section will provide important background information concerning the teratogenicity and mutagenicity of mycophenolate mofetil.

ena steklenica vsebuje 35 g mofetilmikofenolata v 110 g praška za peroralno suspenzijo.
1 bottle contains 35 g mycophenolate mofetil in 110 g powder for oral suspension.

kaspofungin ni vplival na farmakokinetiko amfotericina b, itrakonazola, rifampicina ali mofetilmikofenolata.
caspofungin did not influence the pharmacokinetics of amphotericin b, itraconazole, rifampicin or mycophenolate mofetil.

večkratnega odmerjanja mofetilmikofenolata pri bolnikih s hudo kronično ledvično okvaro še niso proučevali.
multiple dosing of mycophenolate mofetil in patients with severe chronic renal impairment has not been studied.

o primerih prevelikega odmerjanja mofetilmikofenolata so poročali v kliničnih preskušanjih in med trženjem zdravila.
reports of overdoses with mycophenolate mofetil have been received from clinical trials and during post-marketing experience.

farmakokinetičnih parametrov mofetilmikofenolata pri starejših bolnikih (starih 65 let ali več) niso proučevali.
pharmacokinetic behaviour of mycophenolate mofetil in the elderly ( 65 years) has not been formally evaluated.

antacidi z magnezijevimi in aluminijevimi hidroksidi: absorpcija mofetilmikofenolata se ob hkratnem dajanju antacidov zmanjša.
antacids with magnesium and aluminium hydroxides: absorption of mycophenolate mofetil was decreased when administered with antacids.

med zenapaxom in mikofenolno kislino, aktivnim presnovkom mofetilmikofenolata (cellcept®), ni farmakokinetičnih interakcij.
there is no pharmacokinetic interaction between zenapax and mycophenolic acid, the active metabolite of mycophenolate mofetil (cellcept).

sočasno jemanje mofetilmikofenolata ni vplivalo na farmakokinetiko in farmakodinamiko peroralnih kontraceptivov (glejte poglavje 5.2).
the pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by co- administration of mycophenolate mofetil (see also section 5.2).